AGIO
HEALTHCAREAgios Pharm
AI Insight
What's Moving AGIO Today?
No stock-specific AI insight has been generated for AGIO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$22.24$46.00
$35.59
Fundamentals
Market Cap$2.1B
P/E Ratio—
EPS$-7.26
Dividend Yield—
Dividend / Share—
ROE-32.8%
Profit Margin—
Debt / Equity—
Trading
Volume744K
Avg Volume (10D)—
Shares Outstanding59.5M
AGIO News
29 articles- Agios Pharmaceuticals (NASDAQ: AGIO) boosts 2023 stock plan by 2M sharesStock Titan·Jun 19, 2026
- AGIO Stock Surges 35% in Six Months: What's Driving It?Yahoo Finance·Jun 18, 2026
- Agios Pharmaceuticals Inc (AGIO) Earnings Forecast: Future EPS & Revenue Growth EstimatesTradingKey·Jun 18, 2026
- Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain MissMarketbeat·Jun 13, 2026
- Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell DiseaseGlobeNewswire Inc.·Jun 13, 2026
- Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?Yahoo Finance·Jun 4, 2026
- A Look At Agios Pharmaceuticals (AGIO) Valuation After The Cevidoplenib Licensing AgreementSimply Wall Street·Jun 4, 2026
- How The Tebapivat Setback Is Reframing The Story For Agios Pharmaceuticals (AGIO)Yahoo Finance·Jun 3, 2026
- AGIO Secures Global Rights to Late-Stage Rare Blood Disorder CandidateYahoo Finance·Jun 2, 2026
- Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenibProactive Investors·Jun 1, 2026
- AGIO Halts Tebapivat Development in Myelodysplastic SyndromesYahoo Finance·Jun 1, 2026
- Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor CevidoplenibYahoo Finance·Jun 1, 2026
- Agios halts tebapivat development for blood disorderInvesting.com UK·May 30, 2026
- Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?Yahoo Finance·May 29, 2026
- Agios slides after discontinuing development of tebapivat in myelodysplastic syndromes (AGIO)Advfn·May 29, 2026
- Exchange-Traded Funds, Equity Futures Rise Pre-Bell Friday Amid US-Iran Deal HopesYahoo Finance·May 29, 2026
- Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic SyndromesGlobeNewswire Inc.·May 29, 2026
- Allogene CEO to step down; Agios drug fails key testBiopharmadive·May 29, 2026
- AGIO's Pyrukynd Gets Approval for Thalassemia in EuropeYahoo Finance·May 25, 2026
- Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with ThalassaemiaBusiness Wire·May 22, 2026
- Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with ThalassemiaYahoo Finance·May 22, 2026
- Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing AdvancesMarketbeat·May 19, 2026
- Assessing Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price VolatilityYahoo Finance·May 15, 2026
- How Agios’ Mitapivat sNDA And New SCD Trial Design At Agios Pharmaceuticals (AGIO) Has Changed Its Investment StoryYahoo Finance·May 15, 2026
- Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on WednesdayThe Motley Fool·Apr 29, 2026
- Alpha Thalassemia (US, EU4, UK, and Japan) Market Insights, Epidemiology, and Forecasts 2022-2025 & 2025-2036GlobeNewswire Inc.·Apr 13, 2026
- Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ETGlobeNewswire Inc.·Apr 6, 2026
- Why Agios Pharmaceuticals Stock Is Up More Than 21% TodayThe Motley Fool·Mar 31, 2026
- Insider Sells AGIO Shares Worth $82,000 -- But Context Is EverythingThe Motley Fool·Mar 31, 2026
All 29 articles loaded
Price Data
Open$34.82
Previous Close$35.10
Day High$35.80
Day Low$34.63
52 Week High$46.00
52 Week Low$22.24
52-Week Range
$22.24$46.00
$35.59
Fundamentals
Market Cap$2.1B
P/E Ratio—
EPS$-7.26
Dividend Yield—
Dividend / Share—
ROE-32.8%
Profit Margin—
Debt / Equity—
Trading
Volume744K
Avg Volume (10D)—
Shares Outstanding59.5M
About Agios Pharm
Agios Pharmaceuticals, Inc., a biopharmaceutical company, is dedicated to drug discovery and development in the field of cellular metabolism and adjacent areas of biology. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—